Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

D.A. Davidson & CO. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 170.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,520 shares of the medical equipment provider’s stock after acquiring an additional 18,597 shares during the quarter. D.A. Davidson & CO.’s holdings in Zimmer Biomet were worth $2,669,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $30,000. Gen Wealth Partners Inc acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $32,000. Finally, Grove Bank & Trust raised its holdings in shares of Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.6% Shares of ZBH stock opened at $89.69 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The stock has a market cap of $17.35 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 2.68 and a beta of 0.46. The firm’s 50-day moving average is $87.37 and its 200-day moving average is $89.82. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the company posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

Insider Buying and Selling at Zimmer Biomet In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In A number of analysts have recently commented on the stock. Wells Fargo & Company cut their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. Citigroup decreased their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Stifel Nicolaus reduced their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, April 29th. Finally, Barclays decreased their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $100.70.

View Our Latest Report on ZBH

Zimmer Biomet Profile (Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Further Reading Five stocks we like better than Zimmer Biomet The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINED.A. Davidson & CO. Raises Holdings in Rocket Lab Corporation $RKLB

NEXT HEADLINE »Bessemer Group Inc. Buys 47,770 Shares of Amalgamated Financial Corp. $AMAL

, /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be webcast on Wednesday, August 5, 2026 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (800) 330-6710 and using conference ID 7090861. International callers should dial +1 (213) 279-1505 and use conference ID 7090861.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

SOURCE Zimmer Biomet Holdings, Inc.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Zimmer Biomet (ZBH - Free Report) Headquartered in Warsaw, IN, Zimmer Biomet Holdings, Inc. is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries.

ZBH is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 9.93; value investors should take notice.

One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $8.48 per share. ZBH also boasts an average earnings surprise of +4.9%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ZBH should be on investors' short list.

Key Takeaways Pacira will divest iovera to Zimmer Biomet for up to $140M, with closing expected in Q3 2026.PCRX to receive $70M upfront plus up to $70M in potential milestones and plans to reduce debt with the cash. Zimmer Biomet gains iovera rights and will collaborate with PCRX on the registrational spasticity program. Pacira BioSciences (PCRX - Free Report) is reshaping its business through an agreement to divest its iovera medical device franchise to Zimmer Biomet (ZBH - Free Report) for up to $140 million. The deal marks another step in Pacira's strategy to transition toward an innovative biopharmaceutical company while allowing Zimmer Biomet to expand its portfolio of pain management technologies. The closing of the transaction is expected in the third quarter of 2026, subject to customary closing conditions.

The iovera system is an FDA-cleared, drug-free cryoneurolysis device that uses controlled cold therapy to temporarily interrupt peripheral nerve signaling and relieve pain. It is approved for destroying tissue during surgical procedures and creating lesions in peripheral nervous tissue to block pain. It is also indicated for relieving pain and symptoms associated with knee osteoarthritis (OA) for up to 90 days, with some patients experiencing longer-lasting benefits.

The system can also assist with nerve targeting when used with compatible stimulation components. Clinical studies have shown that patients treated with iovera after total knee replacement surgery experienced improved knee symptoms and function, lower pain intensity and a 45% reduction in opioid use during the 12 weeks following surgery.

More on PCRX's iovera Divestiture Deal With ZBHUnder the agreement, Pacira will receive up to $140 million from Zimmer Biomet, consisting of $70 million in upfront cash and potential milestone payments tied to future revenues totaling up to an additional $70 million through Dec. 31, 2031. ZBH will acquire all rights related to the development, manufacturing and commercialization of the iovera platform. Pacira expects to use the upfront proceeds to strengthen its balance sheet, including reducing borrowings under its senior secured revolving credit facility.

The companies will also collaborate on advancing the iovera spasticity program. Pacira could earn incremental compensation if the program successfully completes its registrational study and secures regulatory approval. To facilitate the transfer of the business, the companies plan to establish a customary transition services agreement upon the potential closing of the deal.

Year to date, PCRX shares have lost 2% compared to the industry’s 6.3% growth.

Image Source: Zacks Investment Research

The divestiture aligns with Pacira's broader strategy of sharpening its focus on innovative biopharmaceutical products while monetizing a non-core medical device asset. The cash infusion is expected to enhance financial flexibility, support debt reduction and allow greater emphasis on its long-term growth priorities.

For Zimmer Biomet, the acquisition expands its portfolio with an established, FDA-cleared pain management technology that complements its orthopedic franchise. The company is also expected to leverage its global commercial infrastructure and medical device expertise to broaden adoption of iovera, while the continued collaboration on the spasticity program provides both companies with an opportunity to create additional long-term value.

PCRX’s Other Marketed ProductsApart from the iovera system, Pacira’s marketed product portfolio comprises two drugs — Exparel and Zilretta.

Exparel is PCRX’s flagship pain-management product, initially launched in 2012. It is a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block and a sciatic nerve block in the popliteal fossa for postsurgical pain management.

Zilretta, on the other hand, is approved as an extended-release intra-articular injection for providing relief to OA patients with knee pain.

Pacira is also currently looking to expand Zilretta’s indication to include treatment for OA pain in the shoulder. Enrollment in the phase III registrational study of Zilretta for this indication has been completed, with top-line results expected later this year. Based on the success of the study, the company plans to seek label expansion of the drug for OA pain in the shoulder.

Beyond its marketed products, PCRX is developing a pipeline of clinical-stage therapies for musculoskeletal pain and related indications. Its most advanced candidate, PCRX-201 (enekinragene inzadenovec), is a novel locally administered gene therapy being evaluated in a phase II study for knee OA.

PCRX’s Zacks Rank & Other Stocks to ConsiderPacira currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased from $1.75 to $3.02. Over the same period, EPS estimates for 2027 have also risen from $2.91 to $4.92. LQDA shares have surged 131.1% year to date.

Liquidia’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents, while the same for its 2027 EPS is currently pegged at 87 cents. IMCR shares have lost 8.5% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, with the average surprise being 46.66%.

Zimmer Biomet Holdings trades at a steep valuation discount despite strong free cash flow and high margins. ZBH's entrenched position in orthopedic implants, robust cash generation, and loyal installed base underpin reliable earnings. Recent results show net sales up 9.3%, adjusted EPS up 15.5%, and adjusted gross margin rising to 73.0%.

First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basis First quarter diluted earnings per share were $1.22, an increase of 34.1%; adjusted1 diluted earnings per share were $2.09, an increase of 15.5% Company updates full-year 2026 financial guidance , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2026.  The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency1 basis and an increase of 2.9% on an organic constant currency1 basis.  Net earnings for the first quarter were $238.1 million, or $409.4 million on an adjusted1 basis.

Diluted earnings per share were $1.22 for the first quarter, an increase of 34.1%, and adjusted1 diluted earnings per share were $2.09, an increase of 15.5%.  Zimmer Biomet generated $359.4 million in operating cash flow and $245.9 million of free cash flow in the first quarter.

"We are off to a solid start to the year — strategically, operationally and financially," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "Our first quarter results reflect healthy end markets, continued momentum from our recently launched products and disciplined execution across the business. Given our progress and with our go-to-market transformation proceeding as planned, we are raising our adjusted EPS guidance and free cash flow expectations for the year. We remain confident that our strategy will position Zimmer Biomet for consistent, durable growth over the longer term."

1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.

Recent Highlights

Completed $250 million of share repurchases during the first quarter of fiscal 2026. Named Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer to oversee the strategy, delivery and management of the company's global end-to-end technology portfolio, including AI, robotics, smart implants and data. Completed enrollment in the multi-center clinical study in India of mBôs, a first-of-its-kind, surgeon-guided, autonomous robotic total knee arthroplasty system acquired from Monogram Technologies. This marks a key development milestone and helps ensure future regulatory and commercialization pathways remain on track. First case completed using the G7®TM Acetabular System, a next-generation implant engineered to address challenging primary and revision hip replacement surgeries, following U.S. Food and Drug Administration (FDA) 510(k) clearance in February 2026. Released new data and showcased a broad portfolio of innovations at the 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting, including the full commercial launch of ROSA® Knee with OptimiZe. Named to FORTUNE's 2026 list of America's Most Innovative Companies and to Ethisphere's list of the World's Most Ethical Companies for the second straight year. Launched Phantom® Curved TTC Nail System, a next-generation solution from Paragon 28 subsidiary to support hindfoot fusion procedures. Geographic and Product Category Sales
The following sales table provides results by geography and product category for the three-month period ended March 31, 2026, as well as the percentage change compared to the prior year period, on both a reported basis and a constant currency basis.  Percentage change is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28, Inc. ("Paragon 28").

NET SALES - THREE MONTHS ENDED MARCH 31, 2026

(in millions, unaudited)

Organic

Constant

Constant

Net

Currency

Currency

Sales

% Change

% Change

% Change

Geographic Results

United States

$

1,209.4

8.6

%

8.6

%

3.2

%

International

877.4

10.3

4.2

2.5

Total

$

2,086.7

9.3

%

6.8

%

2.9

%

Product Categories

Knees

United States

$

469.2

2.2

%

2.2

%

2.2

%

International

359.4

7.6

1.3

1.3

Total

828.6

4.5

1.8

1.8

Hips

United States

277.5

5.0

5.0

5.0

International

246.6

6.5

1.0

1.0

Total

524.1

5.7

3.2

3.2

S.E.T. *

562.2

19.5

17.4

1.6

Technology & Data, Bone Cement and Surgical

171.8

14.6

11.7

11.7

Total

$

2,086.7

9.3

%

6.8

%

2.9

%

* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

Amounts reported in millions are computed based on the actual amounts.  As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding.  Percentages presented are calculated from the underlying unrounded amounts.

Financial Guidance

The Company is updating its full-year 2026 financial guidance as follows:

Projected Year Ending December 31, 2026

Previous Guidance

Updated Guidance

2026 Reported Revenue Change

2.5% - 4.5%

2.5% - 4.5%

Foreign Currency Exchange Impact

+0.5 %

+0.5 %

2026 Constant Currency Revenue Change

2.0% - 4.0%

2.0% - 4.0%

2026 Organic Constant Currency Revenue Change(1)

1.0% - 3.0%

1.0% - 3.0%

Adjusted Diluted EPS(2)

$8.30 - $8.45

$8.40 - $8.55

(1)

Excludes the projected impact of the Paragon 28 acquisition through the one-year anniversary of the acquisition date, which is estimated to be approximately 100bps.

(2)

This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts.  See "Forward-Looking Non-GAAP Financial Measures" below, which identifies the information that is unavailable without unreasonable efforts and provides additional information.  It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.

Conference Call

The Company will conduct its first quarter 2026 investor conference call today, April 28, 2026, at 8:30 a.m. ET.  The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be archived for replay following the conference call. 

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.  We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers.  Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.  

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. 

The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release and our commentary in our investor conference call today include non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Net sales change information for the three-month period ended March 31, 2026 is presented on a GAAP (reported) basis and on a constant currency basis. Net sales change for this period is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28.  Constant currency percentage changes exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases.  Projected revenue change information for the year ending December 31, 2026, is also presented on an organic constant currency basis.  In addition to excluding the projected effects of foreign currency exchange rates, projected 2026 organic constant currency revenue change also excludes the projected impact on net sales from the April 2025 acquisition of Paragon 28 through the one-year anniversary of the acquisition date in April 2026.

Net earnings and diluted earnings per share for the three-month periods ended March 31, 2026 and 2025 are presented on a GAAP (reported) basis and on an adjusted basis.  These adjusted financial measures exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in the press release. 

Free cash flow is an additional non-GAAP measure that is presented in this press release.  Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release.  This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts.  These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business.  Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations.  The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.  In addition, constant currency revenue change, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Forward-Looking Non-GAAP Financial Measures

This press release and our commentary in our investor conference call today also include certain forward-looking non-GAAP financial measures for the year ending December 31, 2026.  We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures.  For instance, we exclude the impact of restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; and certain legal and tax matters.  We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures (other than projected 2026 organic constant currency revenue change) to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts.  For example, the timing of certain transactions is difficult to predict because management's plans may change.  In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors.  It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, commitments, strategies or prospects.  All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements.  Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.  These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; the transformation of our sales and distribution network in the U.S. and other markets; challenges relating to the rationalization of our products; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; the risks and uncertainties relating to our ability to successfully execute on our product portfolio rationalization plans; control of costs and expenses; risks related to the ability to realize the anticipated benefits of our acquisitions, including the possibility that the expected benefits from such transactions will not be realized or will not be realized within the expected time period; the risk that acquired businesses will not be integrated successfully; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, service providers, agents, employees, sales representatives and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the effects of natural disasters, or of legal, regulatory or market measures to address natural disasters; the effects of our commitments, goals and disclosures relating to corporate responsibility matters; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection.  A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC).  Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC.  Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary note is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the actual amounts.  As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding.  Certain columns and rows within tables may not add due to the use of rounded numbers.  Percentages presented are calculated from the underlying unrounded amounts.

ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, except per share amounts, unaudited)

2026

2025

Net Sales

$

2,086.7

$

1,909.1

Cost of products sold, excluding intangible asset amortization

576.2

549.8

Intangible asset amortization

162.1

151.0

Research and development

103.4

110.6

Selling, general and administrative

849.9

758.8

Restructuring and other cost reduction initiatives

6.3

36.0

Acquisition, integration, divestiture and related

15.6

10.6

Operating expenses

1,713.5

1,616.8

Operating Profit

373.2

292.3

Other (expense) income, net

(3.0)

2.9

Interest expense, net

(68.8)

(66.2)

Earnings before income taxes

301.3

229.0

Provision for income taxes

63.0

46.5

Net Earnings

238.3

182.6

Less: Net earnings attributable to noncontrolling interest

0.2

0.6

Net Earnings of Zimmer Biomet Holdings, Inc.

$

238.1

$

182.0

Earnings Per Common Share

Basic

$

1.22

$

0.92

Diluted

$

1.22

$

0.91

Weighted Average Common Shares Outstanding

Basic

195.0

198.9

Diluted

195.8

199.7

The condensed consolidated statement of earnings for the three-months ended March 31, 2026, reported in this press release are based on an initial assessment that the Company will not record a goodwill impairment charge in the first quarter 2026.  The Company is finalizing its estimated fair value assessment of such goodwill, and therefore the determination of whether an impairment charge will be recorded, and the amount of any such charge, is not complete and subject to change.  If an impairment charge is recorded, our GAAP net earnings information related to the first quarter of 2026 in this release will differ from what is reported in this release. The final determination regarding any impairment, and the impact on results if there is an impairment, will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, unaudited)

March 31,

December 31,

2026

2025

Assets

Cash and cash equivalents

$

424.2

$

591.9

Receivables, net

1,728.6

1,704.4

Inventories

2,246.8

2,286.4

Other current assets

562.9

537.3

Total current assets

4,962.5

5,119.9

Property, plant and equipment, net

2,211.7

2,207.1

Goodwill

9,931.8

9,947.1

Intangible assets, net

4,547.6

4,717.3

Other assets

1,067.9

1,100.3

Total Assets

$

22,721.6

$

23,091.7

Liabilities and Stockholders' Equity

Current liabilities

$

1,688.4

$

1,996.6

Current portion of long-term debt

1,175.9

587.1

Other long-term liabilities

880.6

870.2

Long-term debt

6,295.1

6,932.0

Stockholders' equity

12,681.6

12,705.8

Total Liabilities and Stockholders' Equity

$

22,721.6

$

23,091.7

ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, unaudited)

2026

2025

Cash flows provided by (used in) operating activities

Net earnings

$

238.3

$

182.6

Depreciation and amortization

270.0

254.4

Share-based compensation

24.2

19.6

Changes in operating assets and liabilities, net of acquired assets and
liabilities

Income taxes

(7.4)

(15.6)

Receivables

14.5

(18.8)

Inventories

(20.9)

(3.0)

Accounts payable and accrued liabilities

(183.0)

(36.4)

Other assets and liabilities

23.5

(0.1)

Net cash provided by operating activities

359.4

382.8

Cash flows provided by (used in) investing activities

Additions to instruments

(77.2)

(59.7)

Additions to other property, plant and equipment

(36.3)

(44.6)

Net investment hedge settlements

(0.3)

1.0

Acquisition of intangible assets

(39.0)

(2.4)

Other investing activities

(6.2)

(0.3)

Net cash used in investing activities

(159.0)

(106.0)

Cash flows provided by (used in) financing activities

Proceeds from senior notes

-

1,748.1

Redemption of senior notes

-

(863.0)

Dividends paid to stockholders

(46.9)

(47.8)

Proceeds from employee stock compensation plans

12.3

16.7

Business combination contingent consideration payments

(69.0)

(17.4)

Debt issuance costs

-

(16.1)

Repurchase of common stock

(250.1)

(229.8)

Other financing activities

(15.6)

(15.2)

Net cash (used in) provided by financing activities

(369.2)

575.4

Effect of exchange rates on cash and cash equivalents

1.1

7.0

Change in cash and cash equivalents

(167.7)

859.1

Cash and cash equivalents, beginning of year

591.9

525.5

Cash and cash equivalents, end of period

$

424.2

$

1,384.5

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED NET SALES % CHANGE TO

CONSTANT CURRENCY AND ORGANIC CONSTANT CURRENCY % CHANGE

(unaudited)

For the Three Months Ended

March 31, 2026 vs. 2025

Organic

Foreign

Constant

Paragon

Constant

Exchange

Currency

28

Currency

% Change

Impact

% Change

Impact

% Change

Geographic Results

United States

8.6

%

-

%

8.6

%

5.4

%

3.2

%

International

10.3

6.1

4.2

1.7

2.5

Total

9.3

%

2.5

%

6.8

%

3.9

%

2.9

%

Product Categories

Knees

United States

2.2

%

-

%

2.2

%

-

%

2.2

%

International

7.6

6.3

1.3

-

1.3

Total

4.5

2.7

1.8

-

1.8

Hips

United States

5.0

-

5.0

-

5.0

International

6.5

5.5

1.0

-

1.0

Total

5.7

2.5

3.2

-

3.2

S.E.T.

19.5

2.1

17.4

15.8

1.6

Technology & Data, Bone
Cement and Surgical

14.6

2.9

11.7

-

11.7

Total

9.3

%

2.5

%

6.8

%

3.9

%

2.9

%

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED TO ADJUSTED RESULTS

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, except per share amounts, unaudited)

FOR THE THREE MONTHS ENDED MARCH 31, 2026

Cost of products
sold, excluding
intangible asset
amortization

Intangible asset
amortization

Restructuring
and other cost
reduction
initiatives

Acquisition,
integration,
divestiture
and related

Other
(expense)
income, net

Provision for
income taxes

Net Earnings
of Zimmer
Biomet
Holdings, Inc.

Diluted
earnings
per
common
share

As Reported

$

576.2

$

162.1

$

6.3

$

15.6

$

(3.0)

$

63.0

$

238.1

$

1.22

Inventory and manufacturing-related
charges(1)

(13.3)

-

-

-

-

3.6

9.7

0.05

Intangible asset amortization(2)

-

(162.1)

-

-

-

34.2

127.9

0.65

Restructuring and other cost reduction
initiatives(3)

-

-

(6.3)

-

-

1.0

5.3

0.03

Acquisition, integration, divestiture and
related(4)

-

-

-

(15.6)

-

1.4

14.2

0.07

Other charges(5)

-

-

-

-

0.8

0.2

0.6

-

Other certain tax adjustments(6)

-

-

-

-

-

(13.5)

13.5

0.07

As Adjusted

$

562.9

$

-

$

-

$

-

$

(2.2)

$

89.9

$

409.4

$

2.09

FOR THE THREE MONTHS ENDED MARCH 31, 2025

Cost of
products sold,
excluding intangible
asset
amortization

Intangible
asset
amortization

Research and
development

Restructuring
and other
cost
reduction
initiatives

Acquisition,
integration,
divestiture
and related

Interest
expense,
net

Provision
for income
taxes

Net
Earnings of
Zimmer
Biomet
Holdings,
Inc.

Diluted
earnings per
common
share

As Reported

$

549.8

$

151.0

$

110.6

$

36.0

$

10.6

$

(66.2)

$

46.5

$

182.0

$

0.91

Inventory and manufacturing-related
charges(1)

(6.2)

-

-

-

-

-

2.1

4.1

0.02

Intangible asset amortization(2)

-

(151.0)

-

-

-

-

28.2

122.8

0.61

Restructuring and other cost
reduction initiatives(3)

-

-

-

(36.0)

-

-

7.2

28.8

0.14

Acquisition, integration, divestiture
and related(4)

-

-

-

-

(10.6)

-

1.9

8.7

0.04

European Union Medical Device
Regulation(7)

-

-

(4.4)

-

-

-

0.9

3.5

0.02

Other charges(5)

-

-

-

-

-

4.8

2.7

2.1

0.01

Other certain tax adjustments(6)

-

-

-

-

-

-

(9.2)

9.2

0.05

As Adjusted

$

543.6

$

-

$

106.2

$

-

$

-

$

(61.4)

$

80.3

$

361.2

$

1.81

(1)

Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue by 2032, inventory step-up expense, and other inventory and manufacturing-related charges or gains.  Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture.  Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense provides investors useful information as to what our costs may have been if we had not been required to increase the inventory's book value to fair value.  The excess and obsolete inventory charges on product lines we intend to discontinue were $1.2 million and $2.6 million in the three-month periods ended March 31, 2026 and 2025, respectively.  Inventory step-up expense was $12.0 million in the three-month period ended March 31, 2026, compared to zero in the same prior year period. 

(2)

We exclude intangible asset amortization as well as deferred tax rate changes on our intangible assets from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization.  Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company.

(3)

In December 2019, 2021 and 2023, and in February and December 2025, we initiated global restructuring programs that included a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making, focus the organization on priorities to drive growth and, in the case of the December 2021 program, to prepare for the spinoff of ZimVie Inc. ("ZimVie").  Restructuring and other cost reduction initiatives also include other cost reduction and optimization initiatives that have the goal of reducing costs or across the organization.  The costs include employee termination benefits; contract terminations for facilities and sales agents; and other charges, such as consulting fees, project management expenses, retention period salaries and benefits and relocation costs. 

(4)

The acquisition, integration, divestiture and related gains and expenses we have excluded from our non-GAAP financial measures resulted from various acquisitions, post-separation costs we have incurred related to ZimVie and gains related to a transition services agreement for services we provide to ZimVie and a transition manufacturing and supply agreement for products we supply to ZimVie for a limited period.  In the three-month periods ended March 31, 2026 and 2025, this line item includes $8.1 million and $1.7 million of expenses, respectively, related to changes in the estimated fair values of contingent consideration due to updated forecasts of net sales from certain acquisitions. 

(5)

We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures.  These include gains and losses from changes in fair value on our equity investments, impairment of instruments related to certain product lines we intend to discontinue, among other various costs.  In addition, in February 2025 we issued senior notes in order to have the necessary cash-on-hand to acquire Paragon 28 once regulatory approval was received.  We have excluded from our non-GAAP financial measures the interest on this debt related to the principal amount of the estimated purchase price and acquisition-related costs up through the acquisition date.  Interest expense subsequent to the acquisition date has not been excluded. 

(6)

Other certain tax adjustments are primarily related to significant and discrete tax adjustments.  The primary adjustments include benefits of $12.1 million and $8.5 million in three-month periods ended March 31, 2026 and 2025, respectively, related to Swiss tax reform.

(7)

The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements.  The new regulations provided a transition period until May 2021 for previously-approved medical devices to meet the additional requirements.  For certain devices, this transition period was extended until May 2024.  A conditional extension of the transition period has been implemented until December 2027 and 2028 depending on the legacy medical device's risk class.  We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our previously-approved medical devices.  The incremental costs primarily relate to temporary personnel and third-party professionals necessary to supplement our internal resources.  Starting January 1, 2026, we do not expect to incur any significant incremental costs related to these new regulations.

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF NET CASH PROVIDED BY OPERATING

ACTIVITIES TO FREE CASH FLOW

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, unaudited)

Three Months Ended March 31,

2026

2025

Net cash provided by operating activities

$

359.4

$

382.8

Additions to instruments

(77.2)

(59.7)

Additions to other property, plant and equipment

(36.3)

(44.6)

Free cash flow

$

245.9

$

278.5

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF GROSS PROFIT & MARGIN

TO ADJUSTED GROSS PROFIT & MARGIN

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, unaudited)

Three Months Ended March 31,

2026

2025

Net Sales

$

2,086.7

$

1,909.1

Cost of products sold, excluding intangible asset amortization

576.2

549.8

Intangible asset amortization

162.1

151.0

Gross Profit

$

1,348.4

$

1,208.3

Inventory and manufacturing-related charges

13.3

6.2

Intangible asset amortization

162.1

151.0

Adjusted gross profit

$

1,523.8

$

1,365.5

Gross margin

64.6

%

63.3

%

Inventory and manufacturing-related charges

0.6

0.3

Intangible asset amortization

7.8

7.9

Adjusted gross margin

73.0

%

71.5

%

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF OPERATING PROFIT & MARGIN TO ADJUSTED OPERATING PROFIT & MARGIN

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(in millions, unaudited)

Three Months Ended
March 31,

2026

2025

Operating profit

$

373.2

$

292.3

Inventory and manufacturing-related charges

13.3

6.2

Intangible asset amortization

162.1

151.0

Restructuring and other cost reduction initiatives

6.3

36.0

Acquisition, integration, divestiture and related

15.6

10.6

European Union Medical Device Regulation

-

4.4

Adjusted operating profit

$

570.5

$

500.5

Operating profit margin

17.9

%

15.3

%

Inventory and manufacturing-related charges

0.6

0.3

Intangible asset amortization

7.8

7.9

Restructuring and other cost reduction initiatives

0.3

1.9

Acquisition, integration, divestiture and related

0.7

0.6

European Union Medical Device Regulation

-

0.2

Adjusted operating profit margin

27.3

%

26.2

%

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE

FOR THE THREE MONTHS ENDED MARCH 31, 2026 and 2025

(unaudited)

Three Months Ended March 31,

2026

2025

Effective tax rate

20.9

%

20.3

%

Tax effect of adjustments made to earnings before taxes(1)

1.6

1.9

Other certain tax adjustments (2)

(4.5)

(4.0)

Adjusted effective tax rate

18.0

%

18.2

%

(1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges

(2) Other certain tax adjustments are primarily related to significant and discrete tax adjustments. The primary adjustments include benefits of $12.1 million and $8.5 million in the three-month periods ended March 31, 2026 and 2025, respectively, related to Swiss tax reform.

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF DEBT TO NET DEBT

AS OF MARCH 31, 2026 and DECEMBER 31, 2025

(in millions, unaudited)

March 31, 2026

December 31, 2025

Debt, both current and long-term

$

7,471.0

$

7,519.1

Cash and cash equivalents

(424.2)

(591.9)

Net debt

$

7,046.8

$

6,927.2

Media

Investors

Troy Kirkpatrick

David DeMartino

614-284-1926

646-531-6115

[email protected] 

[email protected] 

Kirsten Fallon

Zach Weiner

781-779-5561

908-591-6955

[email protected] 

[email protected] 

SOURCE Zimmer Biomet Holdings, Inc.

Zimmer Biomet (ZBH - Free Report) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +12.57%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $2.38 per share when it actually produced earnings of $2.42, delivering a surprise of +1.68%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Zimmer, which belongs to the Zacks Medical - Products industry, posted revenues of $2.09 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.84%. This compares to year-ago revenues of $1.91 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Zimmer shares have added about 3% since the beginning of the year versus the S&P 500's gain of 4.8%.

What's Next for Zimmer?While Zimmer has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Zimmer was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.06 on $2.15 billion in revenues for the coming quarter and $8.37 on $8.52 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Exagen Inc. (XGN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of -20%. The consensus EPS estimate for the quarter has been revised 21.3% lower over the last 30 days to the current level.

Exagen Inc.'s revenues are expected to be $17.13 million, up 10.5% from the year-ago quarter.

Zimmer Biomet (ZBH - Free Report) reported $2.09 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 9.3%. EPS of $2.09 for the same period compares to $1.81 a year ago.

The reported revenue represents a surprise of +1.84% over the Zacks Consensus Estimate of $2.05 billion. With the consensus EPS estimate being $1.86, the EPS surprise was +12.57%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Knees- International: $359.4 million versus $360.34 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.Net Sales- Hips- International: $246.6 million versus $248.43 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.5% change.Net Sales- International: $877.4 million versus the two-analyst average estimate of $868.9 million. The reported number represents a year-over-year change of +10.3%.Net Sales- Hips- United States: $277.5 million versus $270.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5% change.Net Sales- United States: $1.21 billion compared to the $1.2 billion average estimate based on two analysts. The reported number represents a change of +8.6% year over year.Net Sales- Knees- United States: $469.2 million compared to the $470.49 million average estimate based on two analysts. The reported number represents a change of +2.2% year over year.Net Sales- Knees: $828.6 million compared to the $837.59 million average estimate based on five analysts. The reported number represents a change of +4.5% year over year.Net Sales- Technology & Data, Bone Cement and Surgical: $171.8 million compared to the $156.06 million average estimate based on five analysts.Net Sales- S.E.T: $562.2 million compared to the $553.36 million average estimate based on five analysts. The reported number represents a change of +19.5% year over year.Net Sales- Hips: $524.1 million versus $518.97 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.View all Key Company Metrics for Zimmer here>>>

Shares of Zimmer have returned +4.5% over the past month versus the Zacks S&P 500 composite's +12.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zimmer Biomet Q1 Earnings Beat Driven By Tariff Benefit And Solid DemandThe company said the first quarter saw a 20-cent benefit from tariff-related items relative to its expectations.

The orthopedic implant maker reported sales of $2.087 billion, up 9.3% on a reported basis, up 6.8% on a constant currency basis, and 2.9% on an organic constant currency basis, beating the consensus of $2.07 billion.

Knee product sales increased 4.5% to $828.6 million (+1.8% organically), and hip product sales increased 5.7% (+3.2%) to $524.1 million.

Sports Medicine products generated sales of $562.2 million, up 19.5% (+1.6%).

Technology & Data, Bone Cement, and Surgical sales jumped 14.6% (+11.7%) to $171.8 million.

“We are off to a solid start to the year — strategically, operationally, and financially,” said Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet. 

“Our first quarter results reflect healthy end markets, continued momentum from our recently launched products, and disciplined execution across the business,” Tornos said.

CFO Exit Triggers Interim Leadership AppointmentOn Tuesday, Zimmer Biomet said Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations, and Supply Chain, will depart the company effective immediately.

The company has named Paul Stellato, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer, while the company conducts an internal and external search to identify a permanent successor.

Raised Earnings Guidance“Given our progress and with our go-to-market transformation proceeding as planned, we are raising our adjusted EPS guidance and free cash flow expectations for the year. We remain confident that our strategy will position Zimmer Biomet for consistent, durable growth over the longer term,” Tornos further added.

Zimmer Biomet raised fiscal adjusted earnings guidance from $8.30-$8.45 per share to $8.40-$8.55 per share, compared to the consensus of $8.40.

The company reaffirms 2026 sales guidance of $8.44 billion-$8.60 billion versus the consensus of $8.56 billion.

In an investor call on Tuesday, the company said it completed enrollment in a 102-patient clinical study for a fully autonomous AI-driven orthopedic robotic system.

The company expects U.S. approval and the launch of the semiautonomous version in early 2027, followed by the fully autonomous version in late 2027 or early 2028.

In anticipation of the mBos launch, the company is increasing the number of robotic clinical sales representatives, targeting to hire over 200 by the end of 2027.

ZBH Price Action: Zimmer Biomet Holdings shares were down 10.81% at $82.58 at the time of publication on Tuesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Posted by Defense World Staff on Apr 29th, 2026

Cwm LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 60.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 9,377 shares of the medical equipment provider’s stock after selling 14,532 shares during the period. Cwm LLC’s holdings in Zimmer Biomet were worth $843,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Key Financial Inc lifted its stake in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares during the period. Cullen Frost Bankers Inc. lifted its stake in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the period. Root Financial Partners LLC purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $32,000. Finally, Mather Group LLC. purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes A number of analysts have issued reports on ZBH shares. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, April 19th. UBS Group reissued a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Finally, Wells Fargo & Company raised their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $105.95.

Check Out Our Latest Research Report on ZBH

Insider Buying and Selling at Zimmer Biomet In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.28% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance NYSE ZBH opened at $82.95 on Wednesday. The firm has a market capitalization of $16.06 billion, a P/E ratio of 23.43, a P/E/G ratio of 1.89 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a 1-year low of $81.35 and a 1-year high of $108.29. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The business’s 50-day simple moving average is $93.23 and its 200-day simple moving average is $92.89.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company’s revenue was up 9.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.39 EPS for the current year.

Zimmer Biomet Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is currently 27.12%.

Trending Headlines about Zimmer Biomet Here are the key news stories impacting Zimmer Biomet this week:

Positive Sentiment: Q1 results beat expectations — adjusted EPS $2.09 vs. $1.86 estimate and revenue $2.09B, with reported sales up ~9.3% year-over-year and margin expansion, showing underlying business strength. Zimmer Biomet Announces First Quarter 2026 Financial Results Positive Sentiment: Company raised FY-2026 adjusted EPS guidance to $8.40–$8.55 (slightly above consensus) and reiterated revenue targets, supporting forward earnings outlook. Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure Neutral Sentiment: Analyst write-ups highlight strong segment growth, solid organic sales and improved key metrics, but note mixed pre-market reaction (shares dipped despite the beat), indicating some investor profit-taking or concern about near-term execution. ZBH Q1 Earnings & Revenues Top Estimates, Stock Dips in Pre-Market Negative Sentiment: Chief Financial Officer Suketu Upadhyay departed effective April 28; an interim CFO was named. Management turnover in the finance role is creating uncertainty and likely weighing on the stock. Zimmer Biomet Announces Chief Financial Officer Transition Negative Sentiment: Reports of a CEO exit were published alongside the earnings release; headlines about executive departures and the company’s underperformance versus peers amplified investor concern and contributed to the selloff. Zimmer Biomet falls after CEO exit, unchanged growth outlook About Zimmer Biomet (Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

See Also Five stocks we like better than Zimmer Biomet

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEComerica Bank Sells 5,873 Shares of Cintas Corporation $CTAS

NEXT HEADLINE »Comerica Bank Cuts Position in Hilton Worldwide Holdings Inc. $HLT

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Zimmer Biomet (ZBH - Free Report) Headquartered in Warsaw, IN, Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries.

ZBH is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. ZBH has a Growth Style Score of B, forecasting year-over-year earnings growth of 2.9% for the current fiscal year.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.04 to $8.44 per share. ZBH also boasts an average earnings surprise of +4.9%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ZBH should be on investors' short list.

, /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption.

All repurchases are expected to be made under the company's existing $1.5 billion share repurchase authorization, which was approved by the Zimmer Biomet Board of Directors and announced in February 2026. The company has not made any changes to the size, duration or terms of that authorization.

The company may repurchase shares in the open market and/or enter into structured repurchase agreements with third parties. The timing and actual amount of share repurchases will depend on a variety of considerations, including market conditions, the company's stock price, capital availability and alternative uses of capital.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, statements regarding macro pressures, including the impact of such pressures on our business, and any statements about our forecasts, expectations, plans, intentions, commitments, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: competition; pricing pressures; dependence on new product development, technological advances and innovation; changes in customer demand for our products and services caused by demographic changes, obsolescence, development of different therapies or other factors; our ability to attract, retain, develop and maintain adequate succession plans for the highly skilled employees, senior management, independent agents and distributors we need to support our business; the transformation of our sales and distribution network in the U.S. and other markets; challenges relating to the rationalization of our products; shifts in the product category or regional sales mix of our products and services; the risks and uncertainties related to our ability to successfully execute our restructuring plans; the risks and uncertainties relating to our ability to successfully execute on our product portfolio rationalization plans; control of costs and expenses; risks related to the ability to realize the anticipated benefits of our acquisitions, including the possibility that the expected benefits from such transactions will not be realized or will not be realized within the expected time period; the risk that acquired businesses will not be integrated successfully; the effects of business disruptions affecting us, our suppliers, customers or payors, either alone or in combination with other risks on our business and operations; the risks and uncertainties related to our ability to successfully integrate the operations, products, service providers, agents, employees, sales representatives and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; unplanned delays, disruptions and expenses attributable to our enterprise resource planning and other system updates; the ability to form and implement alliances; dependence on a limited number of suppliers for key raw materials and other inputs and for outsourced activities; the risk of disruptions in the supply of materials and components used in manufacturing or sterilizing our products; breaches or failures of our (or of our business partners' or other third parties') information technology systems or products, including by cyberattack, unauthorized access or theft; the outcome of government investigations; the impact of healthcare reform and cost containment measures, including efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, through reductions in reimbursement levels, repayment demands and otherwise; the effects of natural disasters, or of legal, regulatory or market measures to address natural disasters; the effects of our commitments, goals and disclosures relating to corporate responsibility matters; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; changes in tax obligations arising from examinations by tax authorities and from changes in tax laws in jurisdictions where we do business, including as a result of the "base erosion and profit shifting" project undertaken by the Organisation for Economic Co-operation and Development and otherwise; challenges to the tax-free nature of the ZimVie Inc. spinoff transaction and the subsequent liquidation of our retained interest in ZimVie Inc.; the risk of additional tax liability due to the recategorization of our independent agents and distributors to employees; changes in tariffs relating to imports to the U.S. and other countries; the risk that material impairment of the carrying value of our intangible assets, including goodwill, could negatively affect our operating results; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; changes in general industry and market conditions, including domestic and international growth, inflation and currency exchange rates; the domestic and international business impact of political, social and economic instability, tariffs, trade restrictions and embargoes, sanctions, wars, disputes and other conflicts, including on our ability to operate in, export from or collect accounts receivable in affected countries; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and cybersecurity laws; the success of our quality and operational excellence initiatives; the ability to remediate matters identified in inspectional observations issued by the FDA and other regulators, while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

SOURCE Zimmer Biomet Holdings, Inc.

Key Takeaways Abbott completed Exact Sciences acquisition, adding $3B 2026 sales and expanding diagnostics.Zimmer Biomet posts organic growth and EPS gains, driven by new products and efficiency programs.ZBH raised 2026 EPS outlook to $8.40-$8.55 and trades at a lower forward valuation vs. history. Abbott (ABT - Free Report) and Zimmer Biomet (ZBH - Free Report) are two well-established names in the surgical equipment market, which is projected to expand at a CAGR of 8.72% between 2026 and 2032. Abbott, a diversified healthcare giant, has a dedicated Structural Heart portfolio that offers transcatheter and surgical devices for the repair and replacement of heart valves. On the other hand, Zimmer Biomet is a renowned name in the musculoskeletal space, focused on orthopedic reconstructive, sports medicine, trauma and surgical products, alongside integrated digital and robotic technologies.

As of today, Abbott holds a market capitalization of $147.13 billion, significantly larger than Zimmer Biomet’s $16.19 billion valuation. Let’s take a look at both companies to determine which one presents the stronger investment case.

The Case for AbbottThe company recently completed the acquisition of Exact Sciences, a strategic move that adds a new high-growth business to its portfolio and expands its presence into one of the fastest-growing areas of diagnostics. The deal is expected to contribute roughly $3 billion of 2026 incremental sales and support Abbott's long-term sales growth rate. First-quarter 2026 adjusted earnings per share (EPS) of $1.15 came in line with its expectations despite earlier-than-planned financing costs tied to the acquisition.

Core Lab Diagnostic test sales continued to show solid demand trends across the United States, Europe and Latin America, but remained flat in China, where government procurement policies have affected pricing and volumes. A weaker-than-expected respiratory season also weighed on Rapid and Molecular Diagnostics results.

In Nutrition, lower sales volumes persisted across both pediatric and adult product portfolios in the U.S. and international markets. Abbott introduced strategic pricing actions in late 2025 to help accelerate volume growth, which are beginning to show encouraging early signs. The company is also prioritizing innovation, with several nutrition product launches planned over the coming months. 

Meanwhile, Abbott’s Established Pharmaceuticals (EPD) performance benefits from favorable long-term healthcare economic and demographic trends, supported by a broad product offering across five therapeutic areas. The biosimilars portfolio, which includes several market-leading oncology therapies, is a key growth pillar.

Within Medical Devices, the cardiovascular businesses delivered a strong performance in the quarter, supported by the Aveir leadless pacemakers, the Heart Assist Devices portfolio and the launch of two new pulsed field ablation (PFA) catheters. In Diabetes Care, continuous glucose monitoring sales reached $2 billion, although growth was affected by delayed international tender renewal and a difficult prior-year comparison related to shelf restocking dynamics.

Abbott projects full-year 2026 adjusted diluted EPS of $5.38-$5.58, which includes $0.20 of dilution from the Exact Sciences acquisition, and maintains its organic growth outlook of 6.5% to 7.5%.

Here's how estimates for Abbott’s 2026 and 2027 bottom line are trending over the past 60 days.

Image Source: Zacks Investment Research

The Case for Zimmer BiometThe company delivered a solid first-quarter 2026, with sales growing 2.9% on an organic constant currency basis and adjusted EPS rising 15.5% year over year. Healthy end markets and continued momentum from newly-launched products supported the performance. Over the past two years, Zimmer Biomet has addressed key gaps in its core portfolio through the rollout of its “Magnificent 7” platform, which includes products like the Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, and the ROSA Robotic Solutions and navigation technologies.

Within the U.S. hip franchise, the company continues to gain traction with its “triple-play”, comprising Z1 (now representing nearly 40% of U.S. hip stents), the OrthoGrid AI-based hip navigation platform and the HAMMR surgical impactor. Internationally, Zimmer Biomet is seeing rapid adoption of its iodine-coated hip implant in Japan, its second-largest market. Its strategy of offering a comprehensive suite of technology solutions is paying dividends.

Meanwhile, the ongoing transition to a dedicated and specialized U.S. sales channel from independent distributors and sales representatives is already generating improved productivity in transitioned territories. The evolution of go-to-market models, particularly in emerging markets, is also performing in accordance with the company’s plan.

Outside its core, Zimmer Biomet has diversified its portfolio with M&A. Paragon 28’s first-quarter growth accelerated roughly 200 basis points sequentially and is trending back toward double-digit growth. Zimmer Biomet is also advancing toward the anticipated 2027 launch of the mBos, a fully autonomous AI-driven orthopedic robotic system acquired through Monogram Technologies.

Actions such as manufacturing footprint expansion into lower-cost geographies, lowering inventory on hand and an ongoing SKU rationalization program are expected to strengthen Zimmer Biomet’s margins and improve free cash flow conversion rates.

The company reiterated its 2026 organic constant currency revenue growth outlook of 1% to 3% and raised adjusted EPS expectations to the $8.40-$8.55 range.

Take a look at how estimates for the company’s 2026 and 2027 earnings are shaping up.

Image Source: Zacks Investment Research

ABT & ZBH: Price Performance and ValuationSo far this year, ABT shares have dropped 32.6%, lagging both ZBH’s 6.9% decline and the Medical sector’s 7.7% fall.

Image Source: Zacks Investment Research

Abbott is trading at a forward earnings multiple of 14.83, below its median of 22.94 over the last three years. ZBH’s forward earnings multiple sits at 9.67, also lower than its three-year median of 12.73.

Image Source: Zacks Investment Research

ConclusionZimmer Biomet’s latest quarterly performance was shaped by shifting U.S. and certain international go-to-market strategies, while its recent acquisitions are showing positive momentum. The company is also making strides in improving operating efficiency. Meanwhile, Abbott’s first-quarter performance displayed respiratory-testing volatility in Diagnostics, early effects of pricing actions in Nutrition, and strength in EPD and Medical Devices.The Exact Sciences acquisition expands its addressable diagnostics market but presents near-term dilution risk. Estimates for Abbott’s 2025 and 2026 earnings are also trending downward.

On a year-to-date basis, ZBH has shown a stronger performance than Abbott while also appearing relatively more attractive on valuation. Rising earnings projections for the company are highly promising. Existing ZBH holders may find it prudent to retain their position to enjoy long-term momentum.

ZBH carries a Zacks Rank #3 (Hold), while ABT has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Contacts:

Media

Investors 

Troy Kirkpatrick

David DeMartino

614-284-1926

646-531-6115

[email protected] 

[email protected]

Kirsten Fallon

Zach Weiner

781-779-5561

908-591-6955

[email protected] 

[email protected]

SOURCE Zimmer Biomet Holdings, Inc.

Also from this source

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at 10:40 a.m. ET.

A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the fireside chat.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

SOURCE Zimmer Biomet Holdings, Inc.

Also from this source